Table 1.
Univariate analysis for predicting progression-free survival and overall survival.
| Progression-Free Survival | Overall Survival | |||||
|---|---|---|---|---|---|---|
| Median (95%CI) | HR (95% CI) | p-Value | Median (95%CI) | HR (95% CI) | p-Value | |
| Age | ||||||
| <60 | 6.4 (3.6–9.2) | Ref. | 0.92 | 21.9 (2.1–40.2) | Ref. | 0.3 |
| ≥60 | 7.7 (4.6–10.8) | 1.023 (0.633–1.652) | 22.3 (12.2–32.5) | 1.264 (0.811–1.970) | ||
| Gender | ||||||
| Female | 6.4 (2.8–9.9) | Ref. | 0.41 | 17.5 (9.1–25.9) | Ref. | 0.12 |
| Male | 6.9 (5.1–8.6) | 0.826 (0.523–1.305) | 25.4 (17.7–33.1) | 0.684 (0.423–1.107) | ||
| ECOG performance score | ||||||
| 0–1 | 7.2 (5.6–8.7) | Ref. | 0.11 | 25.4 (19.1–31.7) | Ref. | <0.001 |
| ≥2 | 3.5 (2.8–4.2) | 2.096 (0.844–5.206) | 4.1 (3.1–5.1) | 7.657 (3.529–16.612) | ||
| Histopathology | ||||||
| Clear cell | 7.4 (5.8–9.0) | Ref. | 0.4 | 23.9 (14.4–33.4) | Ref. | 0.85 |
| Non-clear cell | 4.3 (2.4–6.1) | 1.233 (0.753–2.018) | 19.7 (9.0–30.4) | 1.051 (0.606–1.824) | ||
| IMDC score, n (%) | ||||||
| Favorable | 20.4 (16.6–24.2) | Ref. | <0.001 | 41.3 (0.5–82.1) | Ref. | 0.004 |
| Intermediate | 6.4 (4.8–8.0) | 3.698 (1.893–7.226) | <0.001 | 20.1 (10.4–29.7) | 1.717 (0.959–3.074) | 0.07 |
| Poor | 3.8 (2.9–4.7) | 6.201 (2.824–13.615) | <0.001 | 12.4 (1.2–23.7) | 3.411 (1.641–7.089) | 0.001 |
| PNI | ||||||
| <48 | 3.8 (3.3–4.2) | Ref. | <0.001 | 12.5 (5.5–19.5) | Ref. | 0.001 |
| ≥48 | 10.9 (7.7–14.0) | 0.444 (0.298–0.662) | 32.3 (17.2–47.5) | 0.460 (0.291–0.726) | ||
| Adjusted IMDCC and PNI model | ||||||
| Favorable | 20.4 (16.6–24.2) | Ref. | <0.001 | 41.3 (0.5–82.1) | Ref. | 0.001 |
| Intermediate (PNI-High) | 10.8 (8.8–12.8) | 2.648 (1.302–5.386) | 0.007 | 30.3 (18.0–42.6) | 1.219 (0622–2.390) | 0.564 |
| Intermediate (PNI-Low) | 3.8 (3.6–3.9) | 5.497 (2.722–11.103) | <0.001 | 12.5 (5.6–19.4) | 2.315 (1.223–4.382) | 0.01 |
| Poor | 3.8 (2.9–4.7) | 6.108 (2.803–13.311) | <0.001 | 12.4 (1.2–23.7) | 3.510 (1.685–7.312) | 0.001 |
| Primary nephrectomy, n (%) | ||||||
| Absent | 3.7 (2.6–4.7) | Ref. | 0.85 | 7.8 (4.5–11.1) | Ref. | <0.001 |
| Present | 7.7 (6.2–9.1) | 0.955 (0.571–1.595) | 30.3 (21.0–39.6) | 0.366 (0.228–0.588) | ||
| Sarcomatoid differentiation, n (%) | ||||||
| Absent | 7.1 (4.0–10.3) | Ref. | 0.59 | 37.0 (26.8–47.2) | Ref. | 0.08 |
| Present | 7.5 (6.5–8.5) | 0.849 (0.465–1.550) | 15.1 (11.1–19.1) | 2.097 (0.913–4.815) | ||
| Metastasectomy, present | 11.6 (4.5–18.8) | 0.616 (0.398–0.952) | 0.03 | 27.5 (15.4–39.6) | 0.728 (0.446–1.187) | 0.2 |
| Lung, present | 11.7 (3.0–20.5) | 0.707 (0.325–1.540) | 0.38 | 34.5 (25.3–43.7) | 0.570 (0.224–1.451) | 0.23 |
| Bone, present | 6.4 (2.8–10.0) | 1.912 (0.828–4.418) | 0.12 | 20.0 (2.7–37.3) | 1.496 (0.552–4.056) | 0.42 |
| Metastatic site | ||||||
| Bone, present | 4.3 (2.1–6.4) | 1.01 (0.677–1.481) | 0.99 | 15.1 (12.0–18.3) | 1.865 (1.190–2.923) | 0.007 |
| Visceral, present | 6.4 (4.4–8.4) | 1.192 (0.599–2.368) | 0.61 | 20.1 (12.2–27.9) | 1.597 (0.768–3.320) | 0.21 |
| Visceral metastasis | ||||||
| Lung, present | 6.8 (5.1–8.5) | 0.934 (0.548–1.593) | 0.8 | 22.3 (12.1–32.6) | 1.183 (0.663–2.109) | 0.56 |
| Liver, present | 4.3 (1.8–6.7) | 1.725 (1.069–2.784) | 0.02 | 13.2 (10.0–16.4) | 1.710 (1.032–2.831) | 0.03 |
| Brain, present | 12.4 (6.9–17.9) | 0.632 (0.318–1.258) | 0.19 | 16.0 (6.6–25.4) | 1.184 (0.569–2.466) | 0.65 |
| Metastasis site number | ||||||
| <3 | 7.4 (5.4–9.4) | Ref. | 0.36 | 32.3 (16.0–48.6) | Ref. | 0.007 |
| ≥3 | 4.2 (1.3–7.2) | 1.208 (0.801–1.819) | 15.1 (7.1–23.2) | 1.831 (1.177–2.851) | ||
| First-line tyrosine kinase option | ||||||
| Sunitinib | 6.0 (3.9–8.0) | Ref. | 0.78 | 25.4 (16.7–34.1) | Ref. | 0.21 |
| Pazopanib | 7.3 (3.6–11.1) | 0.944 (0.618–1.441) | 15.2 (12.5–18.0) | 1.325 (0.846–2.076) | ||